查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2023510

2035年MRI造影劑市場分析與預測：類型、產品、技術、成分、應用、劑型、製程、最終用戶、功能

MRI Contrast Media Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, Form, Process, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球造影造影（MRI）造影劑市場預計將從2025年的39億美元成長到2035年的65億美元，複合年成長率（CAGR）為5.1%。這一成長主要受診斷成像需求不斷成長、MRI技術進步以及慢性疾病患病率上升的推動，後者對先進的診斷成像解決方案提出了更高的要求。 MRI造影劑市場呈現中等程度的整合結構，其中前三大細分市場分別為钆基造影劑（約佔70%的市場佔有率）、鐵基造影劑（20%）和錳基造影劑（10%）。主要應用領域包括神經系統、心血管系統和腫瘤的診斷影像。該市場的成長動力來自診斷影像技術的進步以及對精準診斷程序日益成長的需求。銷售分析表明，全球MRI掃描數量正在穩步成長，每年使用劑量達數百萬劑。

競爭格局由全球性和區域性公司組成，拜耳、通用電氣醫療和布拉科影像等主要企業佔據市場主導地位。創新活動頻繁，重點在於開發更安全、更有效的造影，同時減少副作用。為拓展產品系列和地理企業發展，併購和策略聯盟活動頻繁。近期趨勢表明，由於大環造影劑安全性更高，其研發方向正在轉向此類造影劑，這進一步推動了市場創新和競爭。

市場區隔
類型 順磁性造影劑、超順造影劑及其他
產品 钆基、鐵基、錳基及其他
科技 T1加權影像、T2加權影像等。
成分 活性成分、添加劑及其他
目的 神經病學、心臟病學、腫瘤學、消化病學、肌肉骨骼系統、其他
劑型 注射、口服劑及其他
過程 合成、純化、配製及其他
最終用戶 醫院、診斷影像中心、門診手術中心及其他
功能 造影增強、檢測和其他

在造影造影（MRI）造影劑市場中，「類型」細分至關重要，其中钆基造影劑憑藉其卓越的成像能力和安全性佔據主導地位。這些造影劑主要用於神經系統和血管成像，這主要是由於需要進行詳細診斷成像的慢性疾病日益增多所致。大造影劑也因其較低的腎源性系統性纖維化風險而備受關注，這反映了市場對更安全造影劑的需求趨勢。

在「應用」領域，神經系統和心血管影像技術佔據主導地位，它們對於診斷腫瘤和心臟病等複雜疾病至關重要。神經系統和心血管疾病發生率的上升推動了這一需求，因為這些疾病需要準確、早期的診斷。腫瘤學領域也在成長，這得益於對腫瘤精準檢測和監測的需求，也符合個人化醫療的大趨勢。

在「終端使用者」領域，醫院和影像中心是MRI造影劑的主要消費群體，這主要得益於MRI掃描數量的不斷成長和全球醫療基礎設施的擴張。醫療機構日益重視早期準確診斷是推動需求成長的關鍵因素。科學研究機構也是重要的終端用戶，它們透過探索造影劑的新應用和安全性，推動市場創新。

在「技術」領域，人們明顯傾向於採用先進的診斷成像技術，其中動態造影造影（MRI）因其能夠提供詳細的功能資訊而日益普及。 MRI核磁共振造影系統的進步提高了造影劑的有效性和安全性，也推動了這一趨勢。人工智慧和機器學習在診斷影像技術中的應用預計將進一步推動對先進造影劑解決方案的需求，從而提高診斷準確性並改善患者預後。

區域概覽

北美：北美MRI造影劑市場高度成熟，這得歸功於先進的醫療基礎設施和龐大的MRI掃描量。美國在該地區處於領先地位，醫院和診斷中心的需求量龐大。大型製藥企業的存在以及醫學影像領域的持續研究進一步推動了市場成長。

歐洲：歐洲市場發展較成熟，德國、法國和英國為主要市場參與者。該地區的需求得益於健全的醫療保健體系和慢性病的盛行率上升。法律規範和對病人安全的重視正在推動造影劑的創新。

亞太地區：亞太地區正經歷快速成長，以中國和印度等新興市場為主導。醫療保健投資的增加和人們對疾病早期檢測意識的提高是主要驅動力。儘管該地區的市場仍相對不成熟，但擴大醫療保健服務的覆蓋範圍和發展基礎設施蘊藏著巨大的潛力。

拉丁美洲：拉丁美洲的磁振造影造影劑市場仍處於起步階段，巴西和墨西哥是值得關注的關鍵國家。醫療設施的改善和對先進診斷成像需求的不斷成長是推動市場成長的主要動力。然而，經濟限制和農村地區醫療資源的匱乏是限制市場擴張的挑戰。

中東和非洲：該地區市場尚處於發展初期，阿拉伯聯合大公國和南非是主要參與者。醫療保健投資的增加和醫療旅遊的日益普及推動了市場需求。然而，由於部分國家經濟差距較大以及醫療基礎設施不足，該市場面臨許多挑戰。

主要趨勢和促進因素

磁振造影劑的技術進步

由於造影劑技術的進步，MRI造影劑市場正經歷顯著成長。例如，開發出能夠提高安全性並降低腎源性系統性纖維化風險的大環造影劑等創新技術，正吸引人們的注意。此外，新型造影劑的推出，提高了影像清晰度和診斷準確性，也推動了市場滲透。這些進步對於滿足複雜疾病診斷中對精準診斷工具日益成長的需求至關重要，從而擴大了市場潛力。

監管核准和指南的增加

全球監管機構正在核准新的造影造影（MRI）造影劑，這推動了市場成長。為確保患者安全和造影劑有效性而製定的嚴格指南，增強了醫療專業人員的信心。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）近期核准的新型造影劑，提高了更安全、更有效造影劑的可用性，促進了其廣泛應用。這一趨勢凸顯了遵守監管標準對於推動市場擴張和創新至關重要。

新興市場就業成長

在新興市場，受醫療基礎設施改善和先進診斷技術普及的推動，MRI造影劑的使用量正在激增。這些地區的政府正加大對醫療現代化的投入，包括引進尖端影像技術。隨著人們對早期準確診斷益處的認知不斷提高，對MRI掃描及相關造影劑的需求預計將持續成長，這將為市場相關人員帶來巨大的商機。

人們越來越關注個人化醫療

隨著個人化醫療的興起，客製化診斷方案對於個人化患者照護至關重要，這正在影響著造影劑市場。針對特定患者需求和病情量身訂製的造影劑正日益普及。分子影像技術的進步以及靶向特定生物標記的造影劑的研發，都推動了這一趨勢。隨著個人化醫療的不斷發展，對專用造影劑的需求預計將持續成長，從而推動市場發展。

神經影像診斷應用範圍的擴大

磁振造影造影劑在神經影像學中的廣泛應用是成長要素。隨著阿茲海默症和多發性硬化症等神經系統疾病發生率的上升，對精準影像技術的需求也日益成長。磁振造影造影劑在改善腦部結構和病變的顯像方面發揮著至關重要的作用，有助於早期診斷和治療方案的發展。隨著我們對神經系統疾病認知的不斷深入，預計這一趨勢將持續下去，進一步推動造影劑的需求成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 順磁性造影劑
    • 超順磁性試劑
    • 其他
  • 市場規模及預測：依產品分類
    • 钆系統
    • 鐵基
    • 錳基
    • 其他
  • 市場規模及預測：依應用領域分類
    • 神經病學
    • 循環系統
    • 腫瘤學
    • 胃腸病學
    • 肌肉骨骼系統
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷影像中心
    • 門診手術中心
    • 其他
  • 市場規模及預測：依技術分類
    • T1加權影像
    • T2增強影像
    • 其他
  • 市場規模及預測：以劑型分類
    • 注射藥物
    • 口服
    • 其他
  • 市場規模及預測：依功能分類
    • 增強功能
    • 偵測
    • 其他
  • 市場規模/預測：依成分分類
    • 藥物中的活性成分
    • 添加劑
    • 其他
  • 市場規模及預測：依製程分類
    • 合成
    • 純化
    • 配方
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • GE Healthcare
  • Bayer AG
  • Bracco Imaging
  • Guerbet Group
  • Lantheus Medical Imaging
  • Daiichi Sankyo
  • Spago Nanomedical
  • Jubilant Pharma
  • Trivitron Healthcare
  • Taejoon Pharm
  • Sanochemia Pharmazeutika
  • Subhra Pharma
  • Nano Therapeutics
  • CMR Naviscan
  • YMBioSciences
  • Beijing Beilu Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Zhejiang Hisun Pharmaceutical
  • Shenzhen Mindray Bio-Medical Electronics
  • Shanghai Pharmaceuticals Holding

第9章 關於我們

簡介目錄
Product Code: GIS26839

The global MRI Contrast Media Market is projected to grow from $3.9 billion in 2025 to $6.5 billion by 2035, at a compound annual growth rate (CAGR) of 5.1%. Growth is driven by increasing demand for diagnostic imaging, advancements in MRI technology, and rising prevalence of chronic diseases, necessitating enhanced imaging solutions. The MRI Contrast Media Market is characterized by a moderately consolidated structure, with the top three segments being gadolinium-based agents (approximately 70% market share), iron-based agents (20%), and manganese-based agents (10%). Key applications include neurological, cardiovascular, and oncological imaging. The market is driven by advancements in imaging technologies and increasing demand for accurate diagnostic procedures. Volume insights indicate a steady increase in the number of MRI procedures globally, with millions of doses administered annually.

The competitive landscape features a mix of global and regional players, with major companies like Bayer AG, GE Healthcare, and Bracco Imaging dominating the market. The degree of innovation is high, focusing on developing safer and more effective agents with reduced side effects. Mergers and acquisitions, as well as strategic partnerships, are prevalent as companies aim to expand their product portfolios and geographic reach. Recent trends indicate a shift towards developing macrocyclic agents due to their enhanced safety profiles, driving further innovation and competition in the market.

Market Segmentation
TypeParamagnetic Agents, Superparamagnetic Agents, Others
ProductGadolinium-based, Iron-based, Manganese-based, Others
TechnologyT1-weighted Imaging, T2-weighted Imaging, Others
ComponentActive Pharmaceutical Ingredient, Excipients, Others
ApplicationNeurology, Cardiology, Oncology, Gastroenterology, Musculoskeletal, Others
FormInjectable, Oral, Others
ProcessSynthesis, Purification, Formulation, Others
End UserHospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Others
FunctionalityEnhancement, Detection, Others

In the MRI Contrast Media Market, the 'Type' segment is pivotal, with gadolinium-based agents leading due to their superior imaging capabilities and safety profile. These agents are primarily used in neurological and vascular imaging, driven by the increasing prevalence of chronic diseases requiring detailed diagnostic imaging. Macrocyclic agents are gaining traction due to their lower risk of nephrogenic systemic fibrosis, reflecting a trend towards safer contrast media options.

The 'Application' segment is dominated by neurological and cardiovascular imaging, which are critical in diagnosing complex conditions such as tumors and heart diseases. The demand is propelled by the rising incidence of neurological disorders and cardiovascular diseases, necessitating precise and early diagnosis. The oncology segment is also witnessing growth, driven by the need for accurate tumor detection and monitoring, aligning with the broader trend of personalized medicine.

In the 'End User' segment, hospitals and diagnostic imaging centers are the primary consumers of MRI contrast media, driven by the increasing number of MRI procedures and the expansion of healthcare infrastructure globally. The growing emphasis on early and accurate diagnosis in healthcare facilities is a significant factor contributing to the demand. Research institutions are also notable end users, as they explore new applications and safety profiles of contrast media, fostering innovation in the market.

The 'Technology' segment highlights the shift towards advanced imaging technologies, with dynamic contrast-enhanced MRI gaining popularity for its ability to provide detailed functional information. This trend is supported by technological advancements in MRI machines, which enhance the efficacy and safety of contrast media. The integration of AI and machine learning in imaging technologies is expected to further drive the demand for sophisticated contrast media solutions, as these technologies improve diagnostic accuracy and patient outcomes.

Geographical Overview

North America: The MRI contrast media market in North America is highly mature, driven by advanced healthcare infrastructure and high MRI procedure volumes. The United States leads the region, with significant demand from hospitals and diagnostic centers. The presence of major pharmaceutical companies and ongoing research in medical imaging further bolster market growth.

Europe: Europe exhibits moderate market maturity, with Germany, France, and the UK as key contributors. The region's demand is fueled by a robust healthcare system and increasing prevalence of chronic diseases. Regulatory frameworks and a focus on patient safety drive innovation in contrast media formulations.

Asia-Pacific: The Asia-Pacific region is experiencing rapid growth, with emerging markets like China and India at the forefront. Increasing healthcare investments and rising awareness about early disease detection are key drivers. The region's market is less mature but shows significant potential due to expanding healthcare access and infrastructure development.

Latin America: The MRI contrast media market in Latin America is in the nascent stage, with Brazil and Mexico as notable countries. Growth is supported by improving healthcare facilities and rising demand for advanced diagnostic imaging. Economic constraints and limited healthcare access in rural areas pose challenges to market expansion.

Middle East & Africa: This region shows early-stage market development, with the UAE and South Africa being prominent players. The demand is driven by increasing healthcare investments and a growing focus on medical tourism. However, the market faces challenges due to economic disparities and limited healthcare infrastructure in several countries.

Key Trends and Drivers

Technological Advancements in MRI Contrast Agents

The MRI contrast media market is experiencing significant growth due to technological advancements in contrast agents. Innovations such as the development of macrocyclic agents, which offer improved safety profiles and reduced risk of nephrogenic systemic fibrosis, are gaining traction. Additionally, the introduction of novel agents that enhance image clarity and diagnostic accuracy is driving adoption. These advancements are crucial in addressing the growing demand for precise diagnostic tools in complex medical conditions, thereby expanding the market's potential.

Increasing Regulatory Approvals and Guidelines

Regulatory bodies worldwide are increasingly approving new MRI contrast agents, which is propelling market growth. The establishment of stringent guidelines to ensure patient safety and efficacy of contrast media is fostering trust among healthcare providers. Recent approvals by the FDA and EMA have bolstered the availability of safer and more effective agents, encouraging their widespread adoption. This trend underscores the importance of compliance with regulatory standards in driving market expansion and fostering innovation.

Rising Adoption in Emerging Markets

Emerging markets are witnessing a surge in the adoption of MRI contrast media, driven by improving healthcare infrastructure and increasing access to advanced diagnostic technologies. Governments in these regions are investing in healthcare modernization, which includes the adoption of state-of-the-art imaging technologies. As awareness of the benefits of early and accurate diagnosis grows, the demand for MRI procedures and associated contrast media is expected to rise, presenting significant opportunities for market players.

Growing Focus on Personalized Medicine

The shift towards personalized medicine is influencing the MRI contrast media market, as tailored diagnostic solutions become essential for individualized patient care. Contrast agents that can be customized to specific patient needs and conditions are gaining popularity. This trend is supported by advancements in molecular imaging and the development of agents that target specific biomarkers. As personalized medicine continues to evolve, the demand for specialized contrast media is anticipated to increase, driving market growth.

Expansion of Applications in Neurological Imaging

The expansion of MRI contrast media applications in neurological imaging is a key growth driver. With the increasing prevalence of neurological disorders such as Alzheimer's and multiple sclerosis, there is a heightened need for precise imaging techniques. MRI contrast agents play a critical role in enhancing the visualization of brain structures and pathologies, facilitating early diagnosis and treatment planning. This trend is expected to continue as the understanding of neurological diseases advances, further boosting the demand for contrast media.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Paramagnetic Agents
    • 4.1.2 Superparamagnetic Agents
    • 4.1.3 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Gadolinium-based
    • 4.2.2 Iron-based
    • 4.2.3 Manganese-based
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Neurology
    • 4.3.2 Cardiology
    • 4.3.3 Oncology
    • 4.3.4 Gastroenterology
    • 4.3.5 Musculoskeletal
    • 4.3.6 Others
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Diagnostic Imaging Centers
    • 4.4.3 Ambulatory Surgical Centers
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 T1-weighted Imaging
    • 4.5.2 T2-weighted Imaging
    • 4.5.3 Others
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Injectable
    • 4.6.2 Oral
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Enhancement
    • 4.7.2 Detection
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Active Pharmaceutical Ingredient
    • 4.8.2 Excipients
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Synthesis
    • 4.9.2 Purification
    • 4.9.3 Formulation
    • 4.9.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Form
      • 5.2.1.7 Functionality
      • 5.2.1.8 Component
      • 5.2.1.9 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Form
      • 5.2.2.7 Functionality
      • 5.2.2.8 Component
      • 5.2.2.9 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Form
      • 5.2.3.7 Functionality
      • 5.2.3.8 Component
      • 5.2.3.9 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Form
      • 5.3.1.7 Functionality
      • 5.3.1.8 Component
      • 5.3.1.9 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Form
      • 5.3.2.7 Functionality
      • 5.3.2.8 Component
      • 5.3.2.9 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Form
      • 5.3.3.7 Functionality
      • 5.3.3.8 Component
      • 5.3.3.9 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Form
      • 5.4.1.7 Functionality
      • 5.4.1.8 Component
      • 5.4.1.9 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Form
      • 5.4.2.7 Functionality
      • 5.4.2.8 Component
      • 5.4.2.9 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Form
      • 5.4.3.7 Functionality
      • 5.4.3.8 Component
      • 5.4.3.9 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Form
      • 5.4.4.7 Functionality
      • 5.4.4.8 Component
      • 5.4.4.9 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Form
      • 5.4.5.7 Functionality
      • 5.4.5.8 Component
      • 5.4.5.9 Process
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Form
      • 5.4.6.7 Functionality
      • 5.4.6.8 Component
      • 5.4.6.9 Process
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Form
      • 5.4.7.7 Functionality
      • 5.4.7.8 Component
      • 5.4.7.9 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Form
      • 5.5.1.7 Functionality
      • 5.5.1.8 Component
      • 5.5.1.9 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Form
      • 5.5.2.7 Functionality
      • 5.5.2.8 Component
      • 5.5.2.9 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Form
      • 5.5.3.7 Functionality
      • 5.5.3.8 Component
      • 5.5.3.9 Process
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Form
      • 5.5.4.7 Functionality
      • 5.5.4.8 Component
      • 5.5.4.9 Process
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Form
      • 5.5.5.7 Functionality
      • 5.5.5.8 Component
      • 5.5.5.9 Process
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Form
      • 5.5.6.7 Functionality
      • 5.5.6.8 Component
      • 5.5.6.9 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Form
      • 5.6.1.7 Functionality
      • 5.6.1.8 Component
      • 5.6.1.9 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Form
      • 5.6.2.7 Functionality
      • 5.6.2.8 Component
      • 5.6.2.9 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Form
      • 5.6.3.7 Functionality
      • 5.6.3.8 Component
      • 5.6.3.9 Process
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Form
      • 5.6.4.7 Functionality
      • 5.6.4.8 Component
      • 5.6.4.9 Process
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Form
      • 5.6.5.7 Functionality
      • 5.6.5.8 Component
      • 5.6.5.9 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 GE Healthcare
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bayer AG
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Bracco Imaging
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Guerbet Group
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Lantheus Medical Imaging
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Daiichi Sankyo
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Spago Nanomedical
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Jubilant Pharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Trivitron Healthcare
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Taejoon Pharm
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sanochemia Pharmazeutika
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Subhra Pharma
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Nano Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 CMR Naviscan
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 YMBioSciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Beijing Beilu Pharmaceutical
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Jiangsu Hengrui Medicine
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Zhejiang Hisun Pharmaceutical
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Shenzhen Mindray Bio-Medical Electronics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Shanghai Pharmaceuticals Holding
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us